Claims for Patent: 10,149,876

Summary for Patent: 10,149,876

Title:	Tripterygium wilfordii extracts to overcome chemotherapy resistance
Abstract:	The invention provides extracts and compositions derived from Tripterygium wilfordii for overcoming drug resistance in cancer therapy. This invention relates to organic solvent extracts of T. wilfordii and their use in cancer treatment, particularly in the treatment of cancers which have exhibited resistance to treatment by chemotherapeutic drugs. Methods of treating a cancer are disclosed. The method administers to a patient in need thereof a combination of (a) an organic solvent extract of T. wilfordii and (b) a chemotherapeutic drug. The organic solvent extract of T. wilfordii (a) and chemotherapeutic drug (b) are administered in a combined amount effective to treat the cancer. The cancer being treated is at least in part resistant to treatment by the chemotherapeutic drug (b) alone. Also disclosed are chemotherapeutic compositions comprising a combination of (a) an organic solvent extract of T. wilfordii and (b) a chemotherapeutic drug, wherein (a) and (b) are administered in a combined amount effective to treat the cancer; and a pharmaceutically acceptable carrier.
Inventor(s):	Chow; Moses Sing Sum (Chino Hills, CA), Huang; Ying (Arcadia, CA), Wang; Jinghua Jeffrey (Arcadia, CA), Ravula; Ranadheer (Atlanta, GA), Wang; Zhi Jun (Chino Hills, CA)
Assignee:	WESTERN UNIVERSITY OF HEALTH SCIENCES (Pomona, CA)
Application Number:	14/422,216
Patent Claims:	1. A method of treating a cancer comprising the step of: administering to a patient in need thereof a combination of (a) an organic solvent extract of Tripterygium wilfordii and (b) a chemotherapeutic drug, wherein (a) and (b) are administered in a combined amount effective to treat the cancer, wherein the cancer is at least in part resistant to treatment by the chemotherapeutic drug (b) alone, wherein the organic solvent extract is an ethanol extract, and wherein at least a portion of (a) is administered prior to administration of (b). 2. A method of claim 1, wherein the ethanol extract is identifiable by the MS/LC chromatogram as described in FIG. 2. 3. A method of claim 1, wherein the cancer is breast cancer, leukemia or prostate cancer. 4. A method of claim 1, wherein the chemotherapeutic drug (b) is selected from the group of docetaxel, daurorubicin, trastuzumab, and lapatinib. 5. A method of claim 1, wherein (a) is administered in an amount to increase (b)'s efficacy over the efficacy of (b) when administered alone.

Details for Patent 10,149,876

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2039-02-26
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2039-02-26
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019		2039-02-26